| Year |
Citation |
Score |
| 2022 |
Ferris ST, Ohara RA, Ou F, Wu R, Huang X, Kim S, Chen J, Liu TT, Schreiber RD, Murphy TL, Murphy KM. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunology Research. PMID 35648641 DOI: 10.1158/2326-6066.CIR-21-0865 |
0.332 |
|
| 2020 |
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT, Bagadia P, Liu T, Briseño CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, ... Schreiber RD, et al. cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity. Nature. PMID 32788723 DOI: 10.1038/S41586-020-2611-3 |
0.301 |
|
| 2020 |
Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, ... ... Schreiber RD, et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell. PMID 32783918 DOI: 10.1016/J.Cell.2020.07.013 |
0.432 |
|
| 2019 |
Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, Campian JL, Chicoine MR, Dacey RG, Huang J, Fritsch EF, Gillanders WE, Artyomov MN, Mardis ER, Schreiber RD, et al. Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology. 8: e1561106. PMID 30906654 DOI: 10.1080/2162402X.2018.1561106 |
0.527 |
|
| 2018 |
Theisen DJ, Davidson JT, Briseño CG, Gargaro M, Lauron EJ, Wang Q, Desai P, Durai V, Bagadia P, Brickner JR, Beatty WL, Virgin HW, Gillanders WE, Mosammaparast N, Diamond MS, ... ... Schreiber RD, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science (New York, N.Y.). 362: 694-699. PMID 30409884 DOI: 10.1126/Science.Aat5030 |
0.417 |
|
| 2018 |
Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, ... ... Schreiber RD, et al. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell. PMID 30343900 DOI: 10.1016/J.Cell.2018.09.030 |
0.312 |
|
| 2018 |
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. . 2001. 410: 1107-1111. Journal of Immunology (Baltimore, Md. : 1950). 201: 827-831. PMID 30038035 |
0.758 |
|
| 2018 |
Alspach E, Lussier DM, Schreiber RD. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harbor Perspectives in Biology. PMID 29661791 DOI: 10.1101/cshperspect.a028480 |
0.42 |
|
| 2018 |
Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget. 9: 4109-4119. PMID 29423108 DOI: 10.18632/Oncotarget.23751 |
0.561 |
|
| 2017 |
Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells. Nature Communications. 8: 562. PMID 28916749 DOI: 10.1038/S41467-017-00627-Z |
0.358 |
|
| 2017 |
Lee AJ, Chen B, Chew MV, Barra NG, Shenouda MM, Nham T, van Rooijen N, Jordana M, Mossman KL, Schreiber RD, Mack M, Ashkar AA. Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. The Journal of Experimental Medicine. PMID 28264883 DOI: 10.1084/Jem.20160880 |
0.4 |
|
| 2017 |
Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby M, Graziano RF, Mardis ER, Korman AJ, Schreiber RD. Temporally-Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunology Research. PMID 28073774 DOI: 10.1158/2326-6066.Cir-16-0391 |
0.307 |
|
| 2017 |
Schreiber RD. Abstract IA23: Personalizing cancer immunotherapy Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-Ia23 |
0.442 |
|
| 2016 |
Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP. Endogenous Neoantigen-specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunology Research. PMID 27799140 DOI: 10.1158/2326-6066.Cir-16-0156 |
0.607 |
|
| 2016 |
Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology. 5: e1186314. PMID 27757297 DOI: 10.1080/2162402X.2016.1186314 |
0.383 |
|
| 2016 |
Griffith OL, Chan SR, Griffith M, Krysiak K, Skidmore ZL, Hundal J, Allen JA, Arthur CD, Runci D, Bugatti M, Miceli AP, Schmidt H, Trani L, Kanchi KL, Miller CA, ... ... Schreiber RD, et al. Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Reports. 17: 249-60. PMID 27681435 DOI: 10.1016/J.Celrep.2016.08.076 |
0.396 |
|
| 2016 |
Capietto AH, Chan SR, Ricci B, Allen JA, Su X, Novack DV, Schreiber RD, Faccio R. Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment. Oncotarget. PMID 27391074 DOI: 10.18632/Oncotarget.10443 |
0.377 |
|
| 2016 |
Raju S, Kretzmer LZ, Koues OI, Payton JE, Oltz EM, Cashen A, Polic B, Schreiber RD, Shaw AS, Markiewicz MA. NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo. Journal of Immunology (Baltimore, Md. : 1950). PMID 27183590 DOI: 10.4049/Jimmunol.1501982 |
0.426 |
|
| 2016 |
Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology. 130: 25-74. PMID 26922999 DOI: 10.1016/Bs.Ai.2016.01.001 |
0.484 |
|
| 2016 |
Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T. Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. Embo Reports. PMID 26882544 DOI: 10.15252/Embr.201540726 |
0.434 |
|
| 2016 |
Schreiber RD. Abstract IA05: Personalizing cancer immunotherapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia05 |
0.455 |
|
| 2016 |
Schreiber RD. Abstract IA03: Therapeutically-active neoantigen-specific cancer vaccines Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia03 |
0.453 |
|
| 2016 |
Gubin MM, Ward JP, Noguchi T, Zhang X, Arthur C, Krebber W, Mulder GE, Melief CJM, Gillanders WE, Artyomov M, Mardis ER, Schreiber RD. Abstract A001: Tumor-specific mutant antigens in cancer immunotherapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A001 |
0.44 |
|
| 2016 |
Mardis E, Griffith OL, Szeman RC, Griffith M, Krysiak K, Skidmore Z, Hundal J, Allen JA, Cora A, Miceli AP, Schmidt H, Trani L, Kanchi K, Miller CA, Larson DE, ... ... Schreiber RD, et al. Abstract IA20: Genomics of a STAT1 knockout mouse model of human ER+ breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Ia20 |
0.384 |
|
| 2016 |
Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer Advances in Immunology. DOI: 10.1016/bs.ai.2016.01.001 |
0.348 |
|
| 2015 |
Parikh BA, Piersma SJ, Pak-Wittel MA, Yang L, Schreiber RD, Yokoyama WM. Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells. Plos Pathogens. 11: e1005323. PMID 26720279 DOI: 10.1371/Journal.Ppat.1005323 |
0.434 |
|
| 2015 |
Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science (New York, N.Y.). 350: 158-9. PMID 26450194 DOI: 10.1126/Science.Aad4140 |
0.373 |
|
| 2015 |
Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 162: 1229-41. PMID 26321679 DOI: 10.1016/J.Cell.2015.08.016 |
0.399 |
|
| 2015 |
Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. The Journal of Clinical Investigation. 125: 3413-21. PMID 26258412 DOI: 10.1172/Jci80008 |
0.469 |
|
| 2015 |
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Schreiber RD, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538 |
0.376 |
|
| 2015 |
Chen JQ, Mori H, Cardiff RD, Trott JF, Hovey RC, Hubbard NE, Engelberg JA, Tepper CG, Willis BJ, Khan IH, Ravindran RK, Chan SR, Schreiber RD, Borowsky AD. Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent. Plos One. 10: e0129895. PMID 26075897 DOI: 10.1371/Journal.Pone.0129895 |
0.351 |
|
| 2015 |
Sheehan KC, Lazear HM, Diamond MS, Schreiber RD. Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. Plos One. 10: e0128636. PMID 26010249 DOI: 10.1371/Journal.Pone.0128636 |
0.62 |
|
| 2015 |
Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB. Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host & Microbe. 17: 653-61. PMID 25974304 DOI: 10.1016/J.Chom.2015.04.005 |
0.342 |
|
| 2015 |
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (New York, N.Y.). 348: 69-74. PMID 25838375 DOI: 10.1126/Science.Aaa4971 |
0.476 |
|
| 2015 |
Schreiber RD. Abstract IA08: Using genomics to define the antigenic targets of checkpoint blockade cancer immunotherapy Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Ia08 |
0.466 |
|
| 2015 |
Schreiber R. Abstract IA23: Using genomics to identify tumor specific antigens and inform cancer immunotherapy Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-Ia23 |
0.465 |
|
| 2014 |
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, ... ... Schreiber RD, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515: 577-81. PMID 25428507 DOI: 10.1038/Nature13988 |
0.722 |
|
| 2014 |
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, ... ... Schreiber RD, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine. 20: 1301-9. PMID 25344738 DOI: 10.1038/Nm.3708 |
0.487 |
|
| 2014 |
Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Current Opinion in Immunology. 27: 16-25. PMID 24531241 DOI: 10.1016/J.Coi.2014.01.004 |
0.426 |
|
| 2014 |
Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD. Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis. Cell Death and Differentiation. 21: 234-46. PMID 24037089 DOI: 10.1038/Cdd.2013.116 |
0.751 |
|
| 2013 |
Gmyrek GB, Akilesh HM, Graham DB, Fuchs A, Yang L, Miller MJ, Sandoval GJ, Sheehan KC, Schreiber RD, Diamond MS, Swat W. Loss of DAP12 and FcRγ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs. Plos One. 8: e76145. PMID 24155889 DOI: 10.1371/Journal.Pone.0076145 |
0.596 |
|
| 2013 |
Lee SH, Carrero JA, Uppaluri R, White JM, Archambault JM, Lai KS, Chan SR, Sheehan KC, Unanue ER, Schreiber RD. Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1). Journal of Immunology (Baltimore, Md. : 1950). 191: 4223-34. PMID 24048899 DOI: 10.4049/Jimmunol.1300910 |
0.383 |
|
| 2013 |
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals of the New York Academy of Sciences. 1284: 1-5. PMID 23651186 DOI: 10.1111/Nyas.12105 |
0.764 |
|
| 2013 |
Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (New York, N.Y.). 340: 207-11. PMID 23580529 DOI: 10.1126/Science.1235214 |
0.421 |
|
| 2013 |
Schreiber RD. Abstract IA2: The molecular basis of tumor immunogenicity. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia2 |
0.477 |
|
| 2012 |
Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN. Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. Journal of Immunology (Baltimore, Md. : 1950). 189: 5976-84. PMID 23175700 DOI: 10.4049/Jimmunol.1201477 |
0.354 |
|
| 2012 |
Thackray LB, Duan E, Lazear HM, Kambal A, Schreiber RD, Diamond MS, Virgin HW. Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. Journal of Virology. 86: 13515-23. PMID 23035219 DOI: 10.1128/Jvi.01824-12 |
0.636 |
|
| 2012 |
Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, KC W, Albring JC, Satpathy AT, Rotondo JA, Edelson BT, Kretzer NM, Wu X, Weiss LA, Glasmacher E, Li P, Liao W, ... ... Schreiber RD, et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature. 490: 502-7. PMID 22992524 DOI: 10.1038/Nature11531 |
0.388 |
|
| 2012 |
O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. The Journal of Experimental Medicine. 209: 1869-82. PMID 22927549 DOI: 10.1084/Jem.20112738 |
0.826 |
|
| 2012 |
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Research. 72: 3987-96. PMID 22869585 DOI: 10.1158/0008-5472.Can-12-1337 |
0.675 |
|
| 2012 |
Cheney EE, Wise EL, Bui JD, Schreiber RD, Carayannopoulos LN, Spitzer D, Zafirova B, Polic B, Shaw AS, Markiewicz MA. A dual function of NKG2D ligands in NK-cell activation. European Journal of Immunology. 42: 2452-8. PMID 22740149 DOI: 10.1002/Eji.201141849 |
0.33 |
|
| 2012 |
Wang Y, Swiecki M, Cella M, Alber G, Schreiber RD, Gilfillan S, Colonna M. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host & Microbe. 11: 631-42. PMID 22704623 DOI: 10.1016/J.Chom.2012.05.003 |
0.35 |
|
| 2012 |
Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS, Carlson KE, Jeyakumar M, Katzenellenbogen JA, Schreiber RD, Welch MJ. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1119-26. PMID 22669982 DOI: 10.2967/Jnumed.112.103465 |
0.319 |
|
| 2012 |
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, ... ... Schreiber RD, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482: 400-4. PMID 22318521 DOI: 10.1038/Nature10755 |
0.814 |
|
| 2012 |
Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Research : Bcr. 14: R16. PMID 22264274 DOI: 10.1186/Bcr3100 |
0.735 |
|
| 2012 |
Bui J, O'Sullivan T, Saddawi-Konefka R, Vermi W, Smyth M, Schreiber R. Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity Cancer Research. 72: 526-526. DOI: 10.1158/1538-7445.Am2012-526 |
0.504 |
|
| 2012 |
Wang Y, Swiecki M, Cella M, Alber G, Schreiber R, Gilfillan S, Colonna M. O032 Timing and magnitude of Type I interferon responses by distinct viral sensors impact CD8 T cell exhaustion and chronic infection Cytokine. 59: 512. DOI: 10.1016/J.Cyto.2012.06.066 |
0.364 |
|
| 2011 |
Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, Murphy KM, Schreiber RD, Diamond MS. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. Plos Pathogens. 7: e1002407. PMID 22144897 DOI: 10.1371/Journal.Ppat.1002407 |
0.594 |
|
| 2011 |
Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. The Journal of Experimental Medicine. 208: 2367-74. PMID 22084408 DOI: 10.1084/Jem.20110654 |
0.355 |
|
| 2011 |
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of Experimental Medicine. 208: 1989-2003. PMID 21930769 DOI: 10.1084/Jem.20101158 |
0.755 |
|
| 2011 |
O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD. Cancer immunoediting of the NK group 2D ligand H60a. Journal of Immunology (Baltimore, Md. : 1950). 187: 3538-45. PMID 21876033 DOI: 10.4049/Jimmunol.1100413 |
0.616 |
|
| 2011 |
Edelson BT, Bradstreet TR, Hildner K, Carrero JA, Frederick KE, KC W, Belizaire R, Aoshi T, Schreiber RD, Miller MJ, Murphy TL, Unanue ER, Murphy KM. CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity. 35: 236-48. PMID 21867927 DOI: 10.1016/J.Immuni.2011.06.012 |
0.332 |
|
| 2011 |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New York, N.Y.). 331: 1565-70. PMID 21436444 DOI: 10.1126/Science.1203486 |
0.483 |
|
| 2011 |
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annual Review of Immunology. 29: 235-71. PMID 21219185 DOI: 10.1146/Annurev-Immunol-031210-101324 |
0.762 |
|
| 2011 |
Schreiber RD. CS14-1. Deconstructing Cancer Immunoediting Cytokine. 56: 101. DOI: 10.1016/J.Cyto.2011.07.391 |
0.333 |
|
| 2010 |
Bhattacharyya S, Ratajczak CK, Vogt SK, Kelley C, Colonna M, Schreiber RD, Muglia LJ. TAK1 targeting by glucocorticoids determines JNK and IkappaB regulation in Toll-like receptor-stimulated macrophages. Blood. 115: 1921-31. PMID 20065289 DOI: 10.1182/Blood-2009-06-224782 |
0.352 |
|
| 2010 |
Schreiber R, Nishimura T, Vivier E, Ugolini S, Karin M, Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Kagan V, Tyurin V, Cho HI, Celis E, Knight SC, et al. Immune surveillance and tumor immunity (SY2-5) Chairpersons: Takashi Nishimura, Laurence Zitvogel International Immunology. 22. DOI: 10.1093/Intimm/Dxq285 |
0.412 |
|
| 2009 |
McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, Murphy KM, Colonna M. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. The Journal of Experimental Medicine. 206: 2967-76. PMID 19995959 DOI: 10.1084/Jem.20091181 |
0.402 |
|
| 2009 |
Cao X, Leonard K, Collins LI, Cai SF, Mayer JC, Payton JE, Walter MJ, Piwnica-Worms D, Schreiber RD, Ley TJ. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Research. 69: 8700-9. PMID 19843867 DOI: 10.1158/0008-5472.Can-09-1145 |
0.41 |
|
| 2009 |
Späth GF, Schlesinger P, Schreiber R, Beverley SM. A novel role for Stat1 in phagosome acidification and natural host resistance to intracellular infection by Leishmania major. Plos Pathogens. 5: e1000381. PMID 19381261 DOI: 10.1371/Journal.Ppat.1000381 |
0.365 |
|
| 2009 |
Zindl CL, Kim TH, Zeng M, Archambault AS, Grayson MH, Choi K, Schreiber RD, Chaplin DD. The lymphotoxin LTalpha(1)beta(2) controls postnatal and adult spleen marginal sinus vascular structure and function. Immunity. 30: 408-20. PMID 19303389 DOI: 10.1016/J.Immuni.2009.01.010 |
0.325 |
|
| 2009 |
Schreiber R. Cancer Immunoediting: Immunologic Control and Sculpting of Cancer. Cancer Research. 69. DOI: 10.1158/0008-5472.Sabcs-09-Bs3-1 |
0.36 |
|
| 2009 |
Chan S, Schreiber R. Mammary Tumors in STAT1-Deficient Mice Recapitulate Characteristics of Human Luminal Breast Cancers. Cancer Research. 69: 65-65. DOI: 10.1158/0008-5472.Sabcs-09-65 |
0.428 |
|
| 2008 |
Miller JC, Ma Y, Bian J, Sheehan KC, Zachary JF, Weis JH, Schreiber RD, Weis JJ. A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice. Journal of Immunology (Baltimore, Md. : 1950). 181: 8492-503. PMID 19050267 DOI: 10.4049/Jimmunol.181.12.8492 |
0.42 |
|
| 2008 |
Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (New York, N.Y.). 322: 1097-100. PMID 19008445 DOI: 10.1126/Science.1164206 |
0.62 |
|
| 2008 |
Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B, Gerard C, Hancock WW, Schreiber RD. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 86: 137-47. PMID 18622291 DOI: 10.1097/Tp.0B013E31817B8E4B |
0.369 |
|
| 2008 |
Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology. 84: 988-93. PMID 18515327 DOI: 10.1189/Jlb.1107774 |
0.813 |
|
| 2008 |
Scortegagna M, Cataisson C, Martin RJ, Hicklin DJ, Schreiber RD, Yuspa SH, Arbeit JM. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood. 111: 3343-54. PMID 18199827 DOI: 10.1182/Blood-2007-10-115758 |
0.359 |
|
| 2008 |
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 105: 652-6. PMID 18178624 DOI: 10.1073/Pnas.0708594105 |
0.742 |
|
| 2008 |
Cao X, Collins LI, Cai SF, Mayer JC, Walter MJ, Piwnica-Worms D, Schreiber RD, Ley TJ. IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance Blood. 112: 2558-2558. DOI: 10.1182/Blood.V112.11.2558.2558 |
0.447 |
|
| 2007 |
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450: 903-7. PMID 18026089 DOI: 10.1038/Nature06309 |
0.822 |
|
| 2007 |
Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. Journal of Immunology (Baltimore, Md. : 1950). 178: 7540-9. PMID 17548588 DOI: 10.4049/Jimmunol.178.12.7540 |
0.403 |
|
| 2007 |
Weaver BK, Bohn E, Judd BA, Gil MP, Schreiber RD. ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Molecular and Cellular Biology. 27: 4603-16. PMID 17485448 DOI: 10.1128/Mcb.00223-07 |
0.321 |
|
| 2007 |
Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Current Opinion in Immunology. 19: 203-8. PMID 17292599 DOI: 10.1016/J.Coi.2007.02.001 |
0.459 |
|
| 2007 |
Miletic AV, Graham DB, Montgrain V, Fujikawa K, Kloeppel T, Brim K, Weaver B, Schreiber R, Xavier R, Swat W. Vav proteins control MyD88-dependent oxidative burst. Blood. 109: 3360-8. PMID 17158234 DOI: 10.1182/Blood-2006-07-033662 |
0.31 |
|
| 2006 |
Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 26: 804-19. PMID 17115899 DOI: 10.1089/Jir.2006.26.804 |
0.818 |
|
| 2006 |
van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity. 25: 835-48. PMID 17088087 DOI: 10.1016/J.Immuni.2006.09.010 |
0.338 |
|
| 2006 |
Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nature Reviews. Immunology. 6: 836-48. PMID 17063185 DOI: 10.1038/Nri1961 |
0.82 |
|
| 2006 |
Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, Casrouge A, Yang K, Soudais C, Fieschi C, Santos OF, Bustamante J, Picard C, de Beaucoudrey L, Emile JF, ... ... Schreiber RD, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. Plos Genetics. 2: e131. PMID 16934001 DOI: 10.1371/Journal.Pgen.0020131 |
0.402 |
|
| 2006 |
Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. Journal of Immunology (Baltimore, Md. : 1950). 177: 3260-5. PMID 16920966 DOI: 10.4049/Jimmunol.177.5.3260 |
0.415 |
|
| 2006 |
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology. 90: 1-50. PMID 16730260 DOI: 10.1016/S0065-2776(06)90001-7 |
0.666 |
|
| 2006 |
Pan Q, Kravchenko V, Katz A, Huang S, Ii M, Mathison JC, Kobayashi K, Flavell RA, Schreiber RD, Goeddel D, Ulevitch RJ. NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. Infection and Immunity. 74: 2121-7. PMID 16552041 DOI: 10.1128/Iai.74.4.2121-2127.2006 |
0.379 |
|
| 2006 |
Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. Journal of Immunology (Baltimore, Md. : 1950). 176: 905-13. PMID 16393975 DOI: 10.4049/Jimmunol.176.2.905 |
0.347 |
|
| 2006 |
Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nature Immunology. 7: 33-9. PMID 16311601 DOI: 10.1038/Ni1287 |
0.446 |
|
| 2005 |
Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nature Immunology. 6: 1207-10. PMID 16369561 DOI: 10.1038/Ni1205-1207 |
0.422 |
|
| 2005 |
Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Old LJ, Shiku H. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. Journal of Immunology (Baltimore, Md. : 1950). 175: 4433-40. PMID 16177085 DOI: 10.4049/Jimmunol.175.7.4433 |
0.354 |
|
| 2005 |
Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Interferon-gamma and cancer immunoediting. Immunologic Research. 32: 231-45. PMID 16106075 DOI: 10.1385/Ir:32:1-3:231 |
0.802 |
|
| 2005 |
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nature Immunology. 6: 722-9. PMID 15951814 DOI: 10.1038/Ni1213 |
0.787 |
|
| 2005 |
Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Research. 65: 3447-53. PMID 15833880 DOI: 10.1158/0008-5472.Can-04-4316 |
0.608 |
|
| 2005 |
Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, Shiku H. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. The Journal of Experimental Medicine. 201: 681-6. PMID 15753203 DOI: 10.1084/Jem.20041959 |
0.325 |
|
| 2005 |
Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. Erratum: Corrigendum: A critical function for type I interferons in cancer immunoediting Nature Immunology. 6: 852-852. DOI: 10.1038/Ni0805-852B |
0.741 |
|
| 2004 |
Maldonade RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes Nature. 431: 527-532. PMID 15386021 DOI: 10.1038/Nature02916 |
0.348 |
|
| 2004 |
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21: 137-48. PMID 15308095 DOI: 10.1016/J.Immuni.2004.07.017 |
0.627 |
|
| 2004 |
Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood. 104: 3305-11. PMID 15292059 DOI: 10.1182/Blood-2004-01-0266 |
0.455 |
|
| 2004 |
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annual Review of Immunology. 22: 329-60. PMID 15032581 DOI: 10.1146/Annurev.Immunol.22.012703.104803 |
0.662 |
|
| 2004 |
Schreiber RD, Old LJ, Hayday AC, Smyth MJ. Response to 'A cancer immunosurveillance controversy' Nature Immunology. 5: 4-5. DOI: 10.1038/Ni0104-4 |
0.369 |
|
| 2003 |
Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, Akira S. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. The Journal of Clinical Investigation. 111: 1297-308. PMID 12727921 DOI: 10.1172/Jci17085 |
0.389 |
|
| 2003 |
Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, Chapgier A, Eidenschenk C, Eid P, Al Ghonaium A, Tufenkeji H, Frayha H, Al-Gazlan S, Al-Rayes H, ... Schreiber RD, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nature Genetics. 33: 388-91. PMID 12590259 DOI: 10.1038/Ng1097 |
0.364 |
|
| 2003 |
Schreiber GH, Schreiber RD. Interferon-γ The Cytokine Handbook. 567-601. DOI: 10.1016/B978-012689663-3/50028-4 |
0.771 |
|
| 2002 |
Wang J, Schreiber RD, Campbell IL. STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 99: 16209-14. PMID 12461178 DOI: 10.1073/Pnas.252454799 |
0.346 |
|
| 2002 |
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology. 3: 991-8. PMID 12407406 DOI: 10.1038/Ni1102-991 |
0.807 |
|
| 2002 |
Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends in Immunology. 23: 96-101. PMID 11929133 DOI: 10.1016/S1471-4906(01)02118-4 |
0.367 |
|
| 2002 |
Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & Growth Factor Reviews. 13: 95-109. PMID 11900986 DOI: 10.1016/S1359-6101(01)00038-7 |
0.401 |
|
| 2001 |
Schreiber RD. Measurement of mouse and human interferon gamma. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 6.8. PMID 18432821 DOI: 10.1002/0471142735.Im0608S37 |
0.416 |
|
| 2001 |
Strobl B, Arulampalam V, Is'harc H, Newman SJ, Schlaak JF, Watling D, Costa-Pereira AP, Schaper F, Behrmann I, Sheehan KC, Schreiber RD, Horn F, Heinrich PC, Kerr IM. A completely foreign receptor can mediate an interferon-gamma-like response. The Embo Journal. 20: 5431-42. PMID 11574475 DOI: 10.1093/Emboj/20.19.5431 |
0.36 |
|
| 2001 |
Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, Holland SM, Schreiber RD, Casanova JL. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science (New York, N.Y.). 293: 300-3. PMID 11452125 DOI: 10.1126/Science.1061154 |
0.377 |
|
| 2001 |
Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. Biologic consequences of Stat1-independent IFN signaling. Proceedings of the National Academy of Sciences of the United States of America. 98: 6680-5. PMID 11390995 DOI: 10.1073/Pnas.111163898 |
0.405 |
|
| 2001 |
Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. Stat1-independent regulation of gene expression in response to IFN-gamma. Proceedings of the National Academy of Sciences of the United States of America. 98: 6674-9. PMID 11390994 DOI: 10.1073/Pnas.111164198 |
0.423 |
|
| 2001 |
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410: 1107-11. PMID 11323675 DOI: 10.1038/35074122 |
0.804 |
|
| 2001 |
Hu J, Roy SK, Shapiro PS, Rodig SR, Reddy SP, Platanias LC, Schreiber RD, Kalvakolanu DV. ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. The Journal of Biological Chemistry. 276: 287-97. PMID 10995751 DOI: 10.1074/Jbc.M004885200 |
0.338 |
|
| 2000 |
Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13: 265-76. PMID 10981969 DOI: 10.1016/S1074-7613(00)00026-1 |
0.719 |
|
| 2000 |
Döffinger R, Jouanguy E, Dupuis S, Fondanèche MC, Stephan JL, Emile JF, Lamhamedi-Cherradi S, Altare F, Pallier A, Barcenas-Morales G, Meinl E, Krause C, Pestka S, Schreiber RD, Novelli F, et al. Partial interferon-γ receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection Journal of Infectious Diseases. 181: 379-384. PMID 10608793 DOI: 10.1086/315197 |
0.411 |
|
| 1999 |
Allen PM, Murphy KM, Schreiber RD, Unanue ER. Immunology at 2000 Immunity. 11: 649-651. PMID 10626887 DOI: 10.1016/S1074-7613(00)80139-9 |
0.33 |
|
| 1999 |
Gronowski AM, Hilbert DM, Sheehan KC, Garotta G, Schreiber RD. Baculovirus stimulates antiviral effects in mammalian cells. Journal of Virology. 73: 9944-51. PMID 10559307 DOI: 10.1128/Jvi.73.12.9944-9951.1999 |
0.411 |
|
| 1999 |
Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ Proceedings of the National Academy of Sciences of the United States of America. 96: 8633-8638. PMID 10411927 DOI: 10.1073/Pnas.96.15.8633 |
0.45 |
|
| 1998 |
Rodig S, Kaplan D, Shankaran V, Old L, Schreiber RD. Signaling and signaling dysfunction through the interferon gamma receptor. European Cytokine Network. 9: 49-53. PMID 9831186 |
0.647 |
|
| 1998 |
Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons Annual Review of Biochemistry. 67: 227-264. PMID 9759489 DOI: 10.1146/Annurev.Biochem.67.1.227 |
0.358 |
|
| 1998 |
Thomas HE, Parker JL, Schreiber RD, Kay TW. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. The Journal of Clinical Investigation. 102: 1249-57. PMID 9739059 DOI: 10.1172/Jci2899 |
0.353 |
|
| 1998 |
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America. 95: 7556-61. PMID 9636188 DOI: 10.1073/Pnas.95.13.7556 |
0.742 |
|
| 1998 |
Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM, Schreiber RD. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 93: 373-83. PMID 9590172 DOI: 10.1016/S0092-8674(00)81166-6 |
0.37 |
|
| 1998 |
Tanaka N, Sato M, Lamphier MS, Nozawa H, Oda E, Noguchi S, Schreiber RD, Tsujimoto Y, Taniguchi T. Type I interferons are essential mediators of apoptotic death in virally infected cells Genes to Cells. 3: 29-37. PMID 9581980 DOI: 10.1046/J.1365-2443.1998.00164.X |
0.378 |
|
| 1997 |
Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondanèche MC, Tuerlinckx D, Blanche S, Emile JF, Gaillard JL, Schreiber R, Levin M, Fischer A, Hivroz C, Casanova J. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. Journal of Clinical Investigation. 100: 2658-2664. PMID 9389728 DOI: 10.1172/Jci119810 |
0.362 |
|
| 1997 |
Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB Journal of Biological Chemistry. 272: 14899-14907. PMID 9169460 DOI: 10.1074/Jbc.272.23.14899 |
0.333 |
|
| 1997 |
Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling Journal of Experimental Medicine. 185: 1573-1584. PMID 9151895 DOI: 10.1084/Jem.185.9.1573 |
0.373 |
|
| 1997 |
Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annual Review of Immunology. 15: 563-91. PMID 9143700 DOI: 10.1146/Annurev.Immunol.15.1.563 |
0.372 |
|
| 1997 |
Pinckard JK, Sheehan KCF, Schreiber RD. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells Journal of Biological Chemistry. 272: 10784-10789. PMID 9099731 DOI: 10.1074/Jbc.272.16.10784 |
0.315 |
|
| 1996 |
Harada H, Matsumoto M, Sato M, Kashiwazaki Y, Kimura T, Kitagawa M, Yokochi T, Tan RSP, Takasugi T, Kadokawa Y, Schindler C, Schreiber RD, Noguchi S, Taniguchi T. Regulation of IFN-α/β genes: Evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-α/β Genes to Cells. 1: 995-1005. PMID 9077462 DOI: 10.1046/J.1365-2443.1996.870287.X |
0.38 |
|
| 1996 |
Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. The Journal of Biological Chemistry. 271: 27954-61. PMID 8910398 DOI: 10.1074/Jbc.271.44.27954 |
0.304 |
|
| 1996 |
Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proceedings of the National Academy of Sciences of the United States of America. 93: 7673-8. PMID 8755534 DOI: 10.1073/Pnas.93.15.7673 |
0.392 |
|
| 1996 |
Bach EA, Tanner JW, Marsters S, Ashkenazi A, Aguet M, Shaw AS, Schreiber RD. Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Molecular and Cellular Biology. 16: 3214-21. PMID 8649432 DOI: 10.1128/Mcb.16.6.3214 |
0.36 |
|
| 1996 |
Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology. 26: 1335-41. PMID 8647214 DOI: 10.1002/Eji.1830260624 |
0.389 |
|
| 1996 |
Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84: 431-42. PMID 8608597 DOI: 10.1016/S0092-8674(00)81288-X |
0.397 |
|
| 1996 |
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity. 4: 25-36. PMID 8574849 DOI: 10.1016/S1074-7613(00)80295-2 |
0.338 |
|
| 1995 |
Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. The Journal of Experimental Medicine. 181: 607-17. PMID 7836916 DOI: 10.1084/Jem.181.2.607 |
0.339 |
|
| 1995 |
Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE, Murphy KM. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. The Journal of Experimental Medicine. 181: 1755-62. PMID 7722452 DOI: 10.1084/Jem.181.5.1755 |
0.323 |
|
| 1995 |
Dighe AS, Campbell D, Hsieh CS, Clarke S, Greaves DR, Gordon S, Murphy KM, Schreiber RD. Tissue-specific targeting of gytokine unresponsiveness in transgenic mice Immunity. 3: 657-666. PMID 7584155 DOI: 10.1016/1074-7613(95)90136-1 |
0.414 |
|
| 1995 |
Bach EA, Szabo SJ, Dighe AS, Ashkenazi A, Aguet M, Murphy KM, Schreiber RD. Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (New York, N.Y.). 270: 1215-8. PMID 7502050 DOI: 10.1126/Science.270.5239.1215 |
0.421 |
|
| 1994 |
Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1: 447-56. PMID 7895156 DOI: 10.1016/1074-7613(94)90087-6 |
0.491 |
|
| 1994 |
Greenlund A, Farrar M, Viviano B, Schreiber R. Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). The Embo Journal. 13: 1591-1600. DOI: 10.1002/J.1460-2075.1994.Tb06422.X |
0.633 |
|
| 1993 |
Schreiber RD, Farrar MA. The biology and biochemistry of interferon-gamma and its receptor Gastroenterologia Japonica. 28: 88-94. PMID 8486235 DOI: 10.1007/Bf02782897 |
0.656 |
|
| 1993 |
Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor Annual Review of Immunology. 11: 571-611. PMID 8476573 DOI: 10.1146/Annurev.Iy.11.040193.003035 |
0.629 |
|
| 1993 |
Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, Meltzer MS, Fortier AH. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infection and Immunity. 61: 689-98. PMID 8423095 DOI: 10.1128/Iai.61.2.689-698.1993 |
0.364 |
|
| 1992 |
Bancroft GJ, Schreiber RD, Unanue ER. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunological Reviews. 124: 5-24. PMID 1804781 DOI: 10.1111/J.1600-065X.1991.Tb00613.X |
0.4 |
|
| 1992 |
Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infection and Immunity. 60: 84-9. PMID 1729199 DOI: 10.1128/Iai.60.1.84-89.1992 |
0.442 |
|
| 1992 |
Schreiber RD, Farrar MA, Hershey GK, Fernandez-Luna J. The structure and function of interferon-γ receptors International Journal of Immunopharmacology. 14: 413-419. PMID 1535615 DOI: 10.1016/0192-0561(92)90171-G |
0.632 |
|
| 1992 |
Rogers HW, Sheehan KCF, Brunt LM, Dower SK, Unanue ER, Schreiber RD. Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice Proceedings of the National Academy of Sciences of the United States of America. 89: 1011-1015. PMID 1531270 DOI: 10.1073/Pnas.89.3.1011 |
0.438 |
|
| 1992 |
Jacob CO, Aiso S, Schreiber RD, Mcdevitt HO. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development International Immunology. 4: 611-614. PMID 1510787 DOI: 10.1093/Intimm/4.5.611 |
0.316 |
|
| 1992 |
Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-γ Hepatology. 16: 655-663. PMID 1505908 DOI: 10.1002/Hep.1840160308 |
0.335 |
|
| 1992 |
Farrar MA, Campbell JD, Schreiber RD. Identification of a functionally important sequence in the C terminus of the interferon-γ receptor Proceedings of the National Academy of Sciences of the United States of America. 89: 11706-11710. PMID 1465386 DOI: 10.1073/Pnas.89.24.11706 |
0.646 |
|
| 1992 |
Harty JT, Schreiber RD, Bevan MJ. CD8 T cells can protect against an intracellular bacterium in an interferon γ-independent fashion Proceedings of the National Academy of Sciences of the United States of America. 89: 11612-11616. PMID 1360672 DOI: 10.1073/Pnas.89.23.11612 |
0.307 |
|
| 1991 |
Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach J‐, Chatenoud L. Cascade modulation by anti‐tumor necrosis factor monoclonal antibody of interferon‐γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway European Journal of Immunology. 21: 2349-2353. PMID 1833202 DOI: 10.1002/Eji.1830211009 |
0.366 |
|
| 1991 |
Ferran C, Dy M, Sheehan K, Merite S, Schreiber R, Landais P, Grau G, Bluestone J, Bach J-, Chatenoud L. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clinical and Experimental Immunology. 86: 537-543. PMID 1721015 DOI: 10.1111/J.1365-2249.1991.Tb02966.X |
0.332 |
|
| 1990 |
Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel L, Grau G, Bluestone J, Bach J, Chatenoud L. Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation European Journal of Immunology. 20: 509-515. PMID 2138557 DOI: 10.1002/Eji.1830200308 |
0.354 |
|
| 1989 |
Gray PW, Leong S, Fennie EH, Farrar MA, Pingel JT, Fernandez-Luna J, Schreiber RD. Cloning and expression of the cDNA for the murine interferon γ receptor Proceedings of the National Academy of Sciences of the United States of America. 86: 8497-8501. PMID 2530582 DOI: 10.1073/Pnas.86.21.8497 |
0.629 |
|
| 1989 |
Skidmore BJ, Stamnes SA, Townsend K, Glasebrook AL, Sheehan KCF, Schreiber RD, Chiller JM. Enumeration of cytokine-secreting cells at the single-cell level European Journal of Immunology. 19: 1591-1597. PMID 2507324 DOI: 10.1002/Eji.1830190911 |
0.389 |
|
| 1988 |
Schreiber RD. Validation of a role for endogenously produced IFN gamma in resolution of Listeria monocytogenes infection in mice Advances in Experimental Medicine and Biology. 239: 185-192. PMID 3144157 DOI: 10.1007/978-1-4757-5421-6_18 |
0.365 |
|
| 1988 |
Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (New York, N.Y.). 240: 516-8. PMID 3128869 DOI: 10.1126/Science.3128869 |
0.327 |
|
| 1988 |
Zuckerman SH, Schreiber RD. Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor. Journal of Leukocyte Biology. 44: 187-91. PMID 2970515 DOI: 10.1002/Jlb.44.3.187 |
0.401 |
|
| 1987 |
Meltzer MS, Gilbreath MJ, Crawford RM, Schreiber RD, Nacy CA. Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma. Cellular Immunology. 107: 340-7. PMID 3109744 DOI: 10.1016/0008-8749(87)90242-5 |
0.412 |
|
| 1986 |
Schreiber RD, Celada A, Buchmeier N. The role of interferon-gamma in the induction of activated macrophages. Annales De L'Institut Pasteur. Immunologie. 203-6. PMID 2425717 DOI: 10.1016/S0771-050X(86)80028-6 |
0.348 |
|
| 1985 |
Buchmeier NA, Schreiber RD. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America. 82: 7404-8. PMID 3933006 DOI: 10.1073/Pnas.82.21.7404 |
0.394 |
|
| 1985 |
Anderson J, Byrne JA, Schreiber R, Patterson S, Oldstone MB. Biology of cloned cytotoxic T lymphocytes specific for lymphocyte choriomeningitis virus: Clearance of virus and in vitro properties Journal of Virology. 53: 552-560. PMID 3918175 DOI: 10.1128/Jvi.53.2.552-560.1985 |
0.312 |
|
| 1984 |
Celada A, Gray PW, Rinderknecht E, Schreiber RD. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity Journal of Experimental Medicine. 160: 55-74. PMID 6330272 DOI: 10.1084/Jem.160.1.55 |
0.393 |
|
| 1983 |
Pace JL, Russell SW, Schreiber RD, Altman A, Katz DH. Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proceedings of the National Academy of Sciences of the United States of America. 80: 3782-6. PMID 6407020 DOI: 10.1073/Pnas.80.12.3782 |
0.395 |
|
| 1982 |
Schreiber RD, Altman A, Katz DH. Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor. The Journal of Experimental Medicine. 156: 677-89. PMID 7050288 DOI: 10.1084/Jem.156.3.677 |
0.319 |
|
| 1980 |
Sissons JG, Oldstone MB, Schreiber RD. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. Proceedings of the National Academy of Sciences of the United States of America. 77: 559-62. PMID 6928644 DOI: 10.1073/Pnas.77.1.559 |
0.307 |
|
| 1975 |
Schreiber RD, Noble RW, Reichlin M. Restriction of heterogeneity of goat antibodies specific for human hemoglobin SS. Journal of Immunology (Baltimore, Md. : 1950). 114: 170-5. PMID 803525 |
0.521 |
|
| 1972 |
Noble RW, Reichlin M, Schreiber RD. Studies on antibodies directed toward single antigenic sites on globular proteins. Biochemistry. 11: 3326-32. PMID 4115656 DOI: 10.1021/Bi00768A004 |
0.51 |
|
| Show low-probability matches. |
